Aldeyra Therapeutics Inc ALDX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/01/24 EDT
4.20UNCH (UNCH)
Volume
1,828
Close
4.20UNCH (UNCH)
Volume
537,397
52 week range
1.42 - 11.97
Loading...
  • Open3.96
  • Day High4.30
  • Day Low3.96
  • Prev Close3.94
  • 52 Week High11.97
  • 52 Week High Date06/15/23
  • 52 Week Low1.42
  • 52 Week Low Date10/16/23

Key Stats

  • Market Cap249.541M
  • Shares Out59.41M
  • 10 Day Average Volume0.43M
  • Dividend-
  • Dividend Yield-
  • Beta1.44
  • YTD % Change19.66

KEY STATS

  • Open3.96
  • Day High4.30
  • Day Low3.96
  • Prev Close3.94
  • 52 Week High11.97
  • 52 Week High Date06/15/23
  • 52 Week Low1.42
  • 52 Week Low Date10/16/23
  • Market Cap249.541M
  • Shares Out59.41M
  • 10 Day Average Volume0.43M
  • Dividend-
  • Dividend Yield-
  • Beta1.44
  • YTD % Change19.66

RATIOS/PROFITABILITY

  • EPS (TTM)-0.64
  • P/E (TTM)-6.59
  • Fwd P/E (NTM)-25.93
  • EBITDA (TTM)-42.531M
  • ROE (TTM)-27.73%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)12.64%

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aldeyra Therapeutics Inc

 

Profile

MORE
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and...
Richard Douglas Ph.D.
Independent Chairman of the Board
Todd Brady M.D., Ph.D.
President, Chief Executive Officer, Director
Bruce Greenberg
Senior Vice President - Finance, Interim Chief Financial Officer
Address
131 HARTWELL AVENUE, SUITE 320
Lexington, MA
02421
United States

Top Peers

SYMBOLLASTCHG%CHG
QSI
Quantum-Si Inc
1.80UNCHUNCH
PRLD
Prelude Therapeutics Inc
3.73UNCHUNCH
INMB
INmune Bio Inc
11.60UNCHUNCH
IPSC
Century Therapeutics Inc
3.04UNCHUNCH
OVID
Ovid Therapeutics Inc
3.06UNCHUNCH